-
The CEO of Janssen Pharmaceuticals Korea is confirmed
Time of Update: 2021-06-05
From 2011 to 2015, he served as the head of finance of Xi'an Janssen, and later served as the senior financial director of Johnson & Johnson in Southeast Asia and the chief of the Asia Pacific region of Janssen Finance officer.
-
Li Shuhong resigned as director of Jiangsu Haobo Biomedical and other positions
Time of Update: 2021-06-01
Li Shuhong resigned as a director, secretary of the board of directors and chief financial officer due to personal reasons, and the handover has been completed a few days ago.
-
JAMA published two articles: vaccination of new crown vaccine reduces the risk of asymptomatic infection by 72%-86
Time of Update: 2021-05-22
, Both articles show that compared with medical staff who have not received the new crown vaccine, people who have received the Pfizer-BioNTech BNT162b2 vaccine have a significantly reduced risk of asymptomatic and symptomatic new crown virus infection.
-
Nuocheng Jianhua appoints Zhang Xiangyang as chief medical officer
Time of Update: 2021-03-18
It is reported that Nuocheng Jianhua announced yesterday the appointment of Zhang Xiangyang as the company's chief medical officer, reporting to Dr.
(PR Newswire)It is reported that Nuocheng Jianhua announced yesterday the appointment of Zhang Xiangyang as the company's chief medical officer, reporting to Dr.
-
Sanofi's Sarclisa is recommended by NICE
Time of Update: 2021-03-06
The recommendation is based on data from the ICARIA-MM trial, which demonstrated that Sarclisa plus pom-dex can reduce the risk of disease progress or death in adults by 40 percent.
-
Hua zhong agricultural university "inspired Shiping Fund" was established
Time of Update: 2021-02-25
The fund was set up by Zhang He, a member of the Chinese Academy of Sciences, and Wang Shiping, a professor at Huahua Agricultural University, and his disciples, as well as Chen Dongsheng, a member of the university's rice team and general manager of Fisha Gene, and others.
-
Colorectal cancer candidate drug RCC-33 reduces tumor volume in mice by 27
Time of Update: 2021-02-12
Pharmaceuticals announced today that its ongoing in vivo study, which assesses the potential of its drug candidate, RCC-33, to treat colorectal cancer has been interim results.
both groups were vaccinated against colorectal cancer cells and RCC-33 injections in the periduct (IP) began on the 5th day.
-
Genentek antifibrosis oral therapy was approved by the FDA as a priority for the treatment of patients with specific lung diseases
Time of Update: 2021-01-29
", Esbriet has become the standard treatment for patients with idiopathic pulmonary fibrosis.
, there are still significant unsealed needs in patients with fibrosis lung disease, including UIDD.
-
News! China Prostate Cancer Health Management and Testosterone Management Project launched
Time of Update: 2021-01-06
" Professor Ye Dingwei at the unveiling ceremony to address the depth of ketone testosterone management needs to be standardized according to Zhongshan University Cancer Prevention center urology director, the Chinese Anti-Cancer Association Of the Department of Urology, Professor Zhou Fangjian, deputy chairman of the Oncology Committee, the current medical institutions in the treatment, the beginning is only testosterone, descending treatment, doctors rarely pay attention to the patient's testosterone level.
-
The advent of the most complete wheat genome sequence in history will open up new avenues for breeding
Time of Update: 2020-12-23
results will undoubtedly accelerate the pace of wheat breeding research, and new varieties of high-yielding, drought-resistant, disease-resistant wheat will provide a solution to the food shortage caused by global climate change and population expansion.
-
Crab-eating monkeys suffer from Parkinson's disease
Time of Update: 2020-12-22
"After sequencing 11 known risk genes for Parkinson's disease, we found that the 10-year-old crab-eating monkey carried a mutation in the Parkinson's disease risk gene, and functional experiments confirmed that the mutation had a clear biological function and may have been involved in the disease process," Li Hao, Ph.D., of Kunming Animal Institute, the paper's lead author, told China Science Daily.
-
The measurement of chroma and its uncertainty
Time of Update: 2020-11-28
4 Instrument Uncertainty Assessment 4.1 Instrument Parameter Setting and Sample Selection Instrument: Color-Eye7000A Romometer, Gretag Macbeth, USA; lighting conditions: d/8; observer perspective: 10 degree field of view; light source: D65; calculation formula: CIE1976 L x a x b* ; measurement mode: SCI and SCE mode, respectively; sample selection: select the most commonly encountered color of the test - white palette.
-
Xerava (eravacycline) to treat complex celiac infections: a Phase III clinical trial in China is to be conducted
Time of Update: 2020-09-20
pharmaceutical company Everest Pharmaceuticals recently announced that it has completed its Phase III clinical trial of eravacycline to treat patients with complex cIAI infections in China.
First China Phase III clinical trial is an important milestone for Everest Medicines," said Sunny Zhu, chief medical officer for Infectious Diseases at Everest Medicines.
-
Explore the world of black science and technology more than immediately before the first cancer diagnosis and treatment of black science and technology conference grand opening
Time of Update: 2020-09-19
Oncology Clinic Black Science and Technology Conference, invited top experts in the field of oncology, well-known scholars, industry big curry to share the latest developments and development models of cancer diagnosis and treatment, as well as the difficulties, key points and prospects of cancer treatment applications, for the first time will be academic and industrial joint, through mutual communication, promote the process of cancer health management, promote the innovation of China's cancer diagnosis and treatment model.
-
The departure of senior executives, pharmaceutical companies have been and become the new normal in the pharmaceutical industry
Time of Update: 2020-08-26
, in addition to frequent personnel adjustment, mergers and acquisitions between pharmaceutical companies have also accelerated this year.
also means that volatility in China's pharmaceutical industry, including personnel changes, mergers and acquisitions, will continue over the next few years.
